Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
528 Views
eMediNexus 12 December 2022
On December 11, 2022, a study presented in a plenary session of the annual meeting of the American Society of Hematology showed that patients taking efgartigimod for chronic primary immune thrombocytopenia (ITP) significantly improved platelet counts. Efgartigimod has a novel mechanism of action. It lowers IgG levels without affecting important immune-system components such as lymphocytes, IgG production, or the body’s innate immune system.
The study, called ADVANCE IV, was conducted by researchers from the Georgetown University Medical Center. The study was a phase III, double-blinded clinical trial that included 131 patients with ITP. All patients in the trial had low platelet counts and had at least one ITP treatment before being randomly assigned to the trial.
The findings of the trial showed that patients with chronic ITP who received efgartigimod achieved a significant improvement in sustained platelet response (21.8%) in comparison to the placebo (5%). The study also showed that in 4 of the 6 scheduled visits, more than half of the patients who responded to the drug showed doubled platelet counts.
Dr. Catherine Broome, M.D., an associate professor of medicine at Georgetown University and principal investigator of the study, noted that significant response to the drug was seen in all types of patients regardless of age, disease severity, time since diagnosis, prior ITP treatment, or use of other medications. She added that the most commonly reported side effects of the drug included bruising, headaches, blood in the urine, and rash-like symptoms on the skin related to bleeding.
(Source: https://theprint.in/health/researchers-find-drug-effective-to-treat-autoimmune-blood-disorder/1260987/ )
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}..
High 1-hour Plasma Glucose: Early Indicator of Type 2 Diabetes Risk..
Maintaining Liver Health to Optimize Glycemic Outcomes in Early Type 2.....
Hidden Hazard of Indoor Pollution in COPD..
Recognizing Pitfalls of Point-of-Care Lung Ultrasound..
Risk Factors for Poorly Controlled Severe Preschool Wheeze..
{{Article_Title}}..
India Reports First Human Metapneumovirus (HMPV) Cases in Karnataka..
Two-Year-Old Dies after Wrong Injection Administered by Private Compounder in Jaisalmer..
'Law of the Land' Paramount for Blinkit's Ambulance Services, Says PiyushGoyal..
India Monitors Respiratory Illness Surge amid Reports of HMPV Outbreak in China..
Chhattisgarh High Court Grants Permission for Minor Rape Victim's Abortion..